13721-39-6
13721-39-6 结构式
基本信息
原钒酸钠
原钒酸钠,十二水
正钒酸钠
十二水合原钒酸钠
十二水原钒酸钠
原钒酸钠 十二水
正钒酸钠 十二水
正釩酸鈉
草酸钠 SODIUM OXALATE
钒酸钠
原钒酸钠, 99.9% (METALS BASIS)
SODIUM ORTHOVANADATE
SODIUM ORTHOVANADATE(V)
SODIUM O-VANADATE
SODIUM VANADATE
SODIUM VANADATE, ORTHO
(beta-4)-vanadate(vo43-trisodium
Sodiumorthovanadate,dodecahyd
sodiumtetraoxovanadate(3-)
sodiumvanadate(v)(na3vo4)
sodiumvanadiumoxide(na3vo4)
trisodium(t-4)-vanadate(vo4(3-)
trisodium,(T-4)-Vanadate
trisodiumorthovanadate
trisodiumvanadate
vanadic(ii)acid,trisodiumsalt
Vanadicacidtrisodiumsalt
Sodium orthovanadate dodecahydrate
sodium tetraoxovanadate
trisodium tetraoxovanadate
物理化学性质
安全数据
常见问题列表
PPTPase.
In the presence of oxidizing agents vanadium ions exist as the hydrated monomer of Sodium orthovanadate (vanadate: HVO4 2- or H2VO 4- ) at micromolar concentations near neutral pH. Sodium orthovanadate (vanadate) also begins to polymerize at concentrations greater than 0.1 mM at neutral pH. The yellow-orange solutions of decavanadate can be converted to the colorless solutions of monomeric Sodium orthovanadate (vanadate) by dilution after a period of many hours. The process is hastened by boiling at pH 10, which encourages the kinetically sluggish depolymerization process. Sodium orthovanadate could alter the phosphorylation status of ASK1 at serine 83 and threonine 845 induced by ischemia. Sodium orthovanadate could increase the tyrosine posphorylation of PTEN and further inhibit the activation of ASK1 via activating Akt during cerebral ischemia.
知名试剂公司产品信息
Sodium orthovanadate, - 60 mesh, 99%(13721-39-6)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2024/04/30 | 081104 | 原钒酸钠, 99.9% (metals basis) Sodium orthovanadate, 99.9% (metals basis) | 13721-39-6 | 25g | 1051元 |
| 2024/04/30 | 081104 | 原钒酸钠, 99.9% (metals basis) Sodium orthovanadate, 99.9% (metals basis) | 13721-39-6 | 100g | 3393元 |
| 2024/04/30 | 081104 | 原钒酸钠, 99.9% (metals basis) Sodium orthovanadate, 99.9% (metals basis) | 13721-39-6 | 500g | 13301元 |